Ivonescimab has been approved in combination with pemigatinib and carboplatin for the treatment of patients with advanced or metastatic NSCLC who have progressed after receiving treatment with an EGFR tyrosine kinase inhibitor and have tested positive for EGFR gene mutation. This evidence concerns the gene EGFR and non-small cell lung carcinoma.